Page last updated: 2024-09-04

rhc 3164 and lofepramine hydrochloride

rhc 3164 has been researched along with lofepramine hydrochloride in 1 studies

Compound Research Comparison

Studies
(rhc 3164)
Trials
(rhc 3164)
Recent Studies (post-2010)
(rhc 3164)
Studies
(lofepramine hydrochloride)
Trials
(lofepramine hydrochloride)
Recent Studies (post-2010) (lofepramine hydrochloride)
6011701

Protein Interaction Comparison

ProteinTaxonomyrhc 3164 (IC50)lofepramine hydrochloride (IC50)
Integrin beta-3Homo sapiens (human)0.35
Integrin alpha-IIbHomo sapiens (human)0.35
Glutamate receptor 1Rattus norvegicus (Norway rat)0.3371
Glutamate receptor 2Rattus norvegicus (Norway rat)0.3371
Glutamate receptor 3Rattus norvegicus (Norway rat)0.3371
Glutamate receptor 4Rattus norvegicus (Norway rat)0.3371
Glutamate receptor ionotropic, kainate 1Rattus norvegicus (Norway rat)0.28
Glutamate receptor ionotropic, NMDA 1 Rattus norvegicus (Norway rat)10
Glutamate receptor ionotropic, kainate 2Rattus norvegicus (Norway rat)0.28
Glutamate receptor ionotropic, kainate 3Rattus norvegicus (Norway rat)0.28
Glutamate receptor ionotropic, NMDA 2A Rattus norvegicus (Norway rat)10
Glutamate receptor ionotropic, NMDA 2BRattus norvegicus (Norway rat)10
Glutamate receptor ionotropic, NMDA 2CRattus norvegicus (Norway rat)10
Glutamate receptor ionotropic, kainate 4Rattus norvegicus (Norway rat)0.28
Glutamate receptor ionotropic, NMDA 2DRattus norvegicus (Norway rat)10
Glutamate receptor ionotropic, kainate 5Rattus norvegicus (Norway rat)0.28
Glutamate receptor ionotropic, NMDA 3BRattus norvegicus (Norway rat)10
P2Y purinoceptor 12Homo sapiens (human)0.35
Glutamate receptor ionotropic, NMDA 3ARattus norvegicus (Norway rat)10

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's1 (100.00)2.80

Authors

AuthorsStudies
Bai, R; Jiang, X; Wu, K; Zhang, P; Zhang, Y1

Reviews

1 review(s) available for rhc 3164 and lofepramine hydrochloride

ArticleYear
Functionalized quinoxalinones as privileged structures with broad-ranging pharmacological activities.
    European journal of medicinal chemistry, 2022, Feb-05, Volume: 229

    Topics: Animals; Anti-Allergic Agents; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Inflammatory Agents; Antineoplastic Agents; Antioxidants; Antiviral Agents; Drug Development; Heterocyclic Compounds; Humans; Hypoglycemic Agents; Mice; Neuroprotective Agents; Photochemotherapy; Quinoxalines; Structure-Activity Relationship; Tubulin Modulators

2022